Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Shares of Prima BioMed Ltd (NASDAQ:IMMP) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.44 and traded as low as $0.4205. Prima BioMed shares last traded at $0.4446, with a volume of 2,034,964 shares trading hands.

Trending Headlines about Prima BioMed

Here are the key news stories impacting Prima BioMed this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and SueWallSt, publicized securities class action claims against Immutep, keeping legal overhang front and center for investors. Article Title
• Negative Sentiment: The lawsuit appears tied to allegations around Immutep’s TACTI-004 lung-cancer program, with one notice citing the trial being stopped for futility after enrolling only about half its target, which may reinforce concerns about clinical execution and future prospects. Article Title
• Neutral Sentiment: One market note reported essentially no short interest in the name, so there is no meaningful short-selling signal to offset the legal-driven narrative.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IMMP shares. Robert W. Baird downgraded Prima BioMed from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $7.00 to $1.00 in a report on Friday, March 13th. Maxim Group lowered Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a research note on Saturday, April 18th. Finally, Citizens Jmp downgraded shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $5.50.

Prima BioMed Price Performance

The stock has a 50-day simple moving average of $0.44 and a two-hundred day simple moving average of $1.79.

Prima BioMed (NASDAQ:IMMP) last announced its quarterly earnings results on Friday, January 30th. The biotechnology company reported ($0.10) EPS for the quarter. The firm had revenue of $1.37 million for the quarter.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 2.32% of the stock is owned by institutional investors.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.